Global drug regulators to embrace real-world evidence

Written by | 31 Jul 2022 | Legislative and Regulatory

The European Medicines Agency (EMA) has backed a joint statement by global regulators calling for greater collaboration on the use of real-world evidence in regulatory decision-making.

The potential for taping into real-world data to inform how new medicines are developed, approved and monitored has been rising up the agenda for more than a decade. However, regulatory authorities have been reluctant to embrace a field where the quality of data can vary. The EMA says challenges remain, particularly when it comes to collecting and using real-world evidence from a variety of global sources.

During the COVID-19 pandemic, medicines regulators and researchers worked together to establish or reinforce collaboration allowing efficient sharing of data and experience in relation to real-world evidence. Now, in a statement issued under the International Coalition of Medicines Regulatory Authorities, it seems leading medicines decision-makers plan to step up their collaboration in this area.

The ICMRA, which includes the EMA, the US FDA and Health Canada, pledges to further enable the integration of real-world evidence into regulatory decision-making. Regulators have committed to greater harmonisation of terminologies and common approaches to developing guidance for industry and others.

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.